Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brexit

Set Alert for Brexit

'Get Your Skates On', UK Firms Planning M&A Warned

UK pharma groups planning M&A deals ‘must get their skates on’ and begin filing now if they want to benefit from the EU’s review process before the Brexit transition period ends on 31 December.

Companies Regulation M & A

Brexit Finally Here But Uncertainty Not Over For Biopharma

A free trade deal needs to be negotiated in record time and UK life sciences must face up to diverging from the EU.

Europe United Kingdom Brexit

Latest From Brexit

Rerouting Drug Supplies ‘A Priority’ After Brexit Transition Ends

Pharmaceutical companies in the UK have again been asked to ensure they have contingency measures in place to deal with potential supply problems at channel ports – this time in preparation for the UK’s formal departure from the EU’s single market and customs union at the beginning of 2021. The industry is continuing to push for a mutual recognition agreement on drug regulation.

United Kingdom Brexit

Medtechs’ View Of UK Brexit Deal: More Certainty, But Still No Detail

COVID-19 is of no lesser importance to the UK medtech industry, but attention is now refocusing on Brexit, future regulation and trade deals.

United Kingdom EU

Industry Laments UK Change To SPC Waiver Approach

Changes to how the UK plans to implement the supplementary protection certificate manufacturing waiver after it separates itself fully from the EU following the current Brexit transition period have been criticized by the generics industry, while originators have welcomed the move.

Brexit Intellectual Property

UK Pharma Exports To Fall 22% In No-Deal Brexit

A new report says that a free trade deal complete with a pharmaceutical mutual recognition agreement is needed to mitigate the damage Brexit will inflict on the global competitiveness of both the UK and the EU.

Brexit Manufacturing

UK Pulls Out Of Unified Patent Court Agreement

The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.

Europe Germany

One Country, Two Regulatory Systems: Another Brexit Headache

The Northern Ireland Protocol brings added complexities that for medicines regulation in the UK, particularly in areas such as new drug approvals and batch release procedures.

Europe United Kingdom

UK Health Care At The Crossroads As Medtechs Watch For Bill, Brexit And NHS Change

The UK health care system is keen to reshape in light of the lessons learned from COVID-19, but it comes at a time when Brexit trade issues and device regulatory system changes are already muddying the waters.

United Kingdom Regulation

EU Issues Post-Brexit Clinical Trial Warning

The UK’s departure from the EU imposes a number of requirements on sponsors running EU trials, but it seems that many have still not taken steps to fall into line. 

Europe United Kingdom

Expectations Are High For New EMA Boss

Emer Cooke seems set to take over as head of the European Medicines Agency – one of the world's most powerful regulatory bodies – before the end of the year. We report on the reaction of a range of pharmaceutical sector stakeholders to her nomination.

Europe Leadership
See All
UsernamePublicRestriction

Register